Aigen Investment Management LP Purchases Shares of 22,316 Bausch Health Companies Inc. (NYSE:BHC)

Aigen Investment Management LP acquired a new position in shares of Bausch Health Companies Inc. (NYSE:BHC) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 22,316 shares of the company’s stock, valued at approximately $180,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BHC. Charles Schwab Investment Management Inc. increased its position in Bausch Health Companies by 1.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,284,036 shares of the company’s stock valued at $10,375,000 after purchasing an additional 14,558 shares during the period. Handelsbanken Fonder AB boosted its stake in shares of Bausch Health Companies by 18.4% in the 4th quarter. Handelsbanken Fonder AB now owns 65,100 shares of the company’s stock valued at $525,000 after purchasing an additional 10,100 shares during the last quarter. Principal Securities Inc. increased its position in shares of Bausch Health Companies by 39.7% during the fourth quarter. Principal Securities Inc. now owns 19,220 shares of the company’s stock worth $155,000 after buying an additional 5,464 shares during the period. Tobam raised its stake in Bausch Health Companies by 10.4% during the fourth quarter. Tobam now owns 15,034 shares of the company’s stock worth $121,000 after buying an additional 1,422 shares during the last quarter. Finally, DGS Capital Management LLC acquired a new position in Bausch Health Companies in the fourth quarter valued at $143,000. 78.65% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on BHC. Jefferies Financial Group reiterated a “hold” rating and set a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. Royal Bank of Canada cut their target price on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $7.42.

Bausch Health Companies Price Performance

BHC stock opened at $7.14 on Monday. The company’s 50-day moving average is $7.31 and its 200-day moving average is $7.63. The stock has a market capitalization of $2.63 billion, a PE ratio of -59.45, a price-to-earnings-growth ratio of 0.37 and a beta of 0.59. Bausch Health Companies Inc. has a 1 year low of $3.96 and a 1 year high of $11.46.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. The firm had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.51 billion. On average, analysts anticipate that Bausch Health Companies Inc. will post 4.41 earnings per share for the current fiscal year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.